hotspot -WSS

hotspot

author：knowledge 2025-10-01 12:12:08 - browse：7743

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Mike Pence clashes with Tucker Carlson in Iowa

WSS

Grail faces three suits alleging harassment, retaliation

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Mirador, a new biotech startup, launches with $400 million

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Congress likely to miss an opportunity to fix drug shortages issue

Adam's Take: Intra

hotspot

hotspot

knowledge

Alkermes shareholders re

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Moonlake's readout produced a cash windfall. Risks remain

Care demand spikes challenge UnitedHealth’s provider arm

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage insurers pressure Biden for bigger payments

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cancer, immunology, HIV research ensnared in fetal tissue politics

Apple is now the first public company to be valued at $3 trillion

Cancer, immunology, HIV research ensnared in fetal tissue politics

entertainment

Care demand spikes challenge UnitedHealth’s provider arm

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Care demand spikes challenge UnitedHealth’s provider arm

Europe sees delivery challenges ahead on Alzheimer's therapies

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Surgeons perform first xenotransplant using CRISPR'd pig kidney

entertainment

entertainment

focus

hotspot